Monday-Friday | 8:30am to 5:00pm
Click here to view Dr. Russo's Webisode: Charles D. Russo, MD, FACC
Notable Work Experience
Board of Directors, North Ridge Medical Center (1996-2000)
Chief of Staff, North Ridge Medical Center (1996-1998)
Vice Chief of Staff, North Ridge Medical Center (1994-1996)
American Board of Internal Medicine
American Board of Internal Medicine, Cardiovascular Medicine
American Board of Clinical Lipidology
Certification Council of Nuclear Cardiology
Residency, Internal Medicine - Hartford Hospital - Hartford, CT (1982-1984)
Chief Resident, Advanced Fellow in Internal Medicine - Hartford Hospital - Hartford, CT (1984-1985)
New York Medical College - M.D. - Valhalla, NY (1981)
Fordham University - B.S. - Bronx, NY (1977)
American College of Cardiology
Alpha Omega Alpha
Broward County Medical Association
National Lipid Association
Society of CT Angiography
American College of Physicians
Cum Laude, Fordham University
Alpha Omega Alpha, New York Medical College
Howard Levine, MD Science Award, Hartford Capital Area Health Consortium, New Britain General Hospital, "Non-Invasive Shunt Determination by Acetylene Uptake"
Martin H. Stein, Memorial Award for Superior Performance as a Cardiology Fellow, University of Miami, Jackson Memorial Hospital
"Aristotle" Apixiban for reduction in stroke and other thromboembolic events in atrial fibrillation, factor inhibitor" Principal Investigator: Charles D. Russo, MD. (2007-2009).
"Phase III international randomized, double-blind placebo controlled trial evaluating the efficacy and safety of orbofiban in patients with unstable coronary syndromes." The OPUS-TIMI 16 Trial: Searle & Co. Pharmaceutical. Principal Investigator: Louis J. Cioci, MD. Co-Investigator: Charles D. Russo, MD (1998-Present).
Sudden cardiac death and heart failure trial (SCD-HeFT). National Institutes of Health. Principal Investigator: Richard Luceri, MD. Co-Investigator: Charles D. Russo, MD (1998-2003).
"MIL-SW-027 A double-blind, randomized, multicenter study to evaluate the effectiveness of intravenous milrinone versus placebo in reducing the number of days of hospitalization in the 60 days following entry into the study for treatment of left-sided heart failure." (OPTIME). Principal Investigator: Louis J. Cioci, MD. Co-Investigator: Charles D. Russo, MD (1998-2004).
Presentation: Rebreathing Society Meeting. Stratford Mountain, VT. "Determination of Adriamycin Cardiotoxicity by Exercise Acetylene Cardiac Outputs" (1985).
Presentation: Rebreathing Society Meeting. Stratford Mountain, VT. "Non-Invasive Right-to-Left Shunt Determination by Acetylene Rebreathing" (1985).
S.L.E. Research - New York University. Bellvue Hospital "Definition of the Sm Antigen" (1973).
"An improved method for production of intravenous contrast during echocardiography," J. Clin. Ultrasound 17:pp 132-136. February 1989.
"Determination of aortic valve area by two-dimensional and doppler echocardiography in patients with normal and stenotic bioprosthetic valves," JACC Vol 15, No 4, March 15, 1990: pp 817-824.
"Compression of an anomalous left circumflex coronary artery by a bioprosthetic valve ring," Journal of Cardiovascular Surgery Vol. 31 No 1: pp 52-54. Jan/Feb 1990.
Diagnosis of Bioprosthetic Aortic Stenosis: Measurement of Valve Area by Two-Dimensional and Doppler Echocardiography (1987).
Doppler Assessment of Left Ventricular Flow Signals During Amyl Nitrate Administration.
Charles D. Russo, MD, FACC and Darlene Moppert, MS, RD, LD/N. The Fort Lauderdale Diet: A Cardiologist's Solution to the Calorie Calamity. (2007)